2018
Long-Term Survivors of Pancreatic Cancer
Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer. Pancreas 2018, 47: 958-966. PMID: 30074526, PMCID: PMC6095724, DOI: 10.1097/mpa.0000000000001133.Peer-Reviewed Original ResearchConceptsLong-term survivalPancreatic cancerPancreatic adenocarcinomaCalifornia Cancer RegistryLong-term survivorsPancreatic cancer mortalityAsian/Pacific IslandersNational Cancer InstituteNon-Hispanic whitesAdjuvant chemotherapyUnresectable patientsBaseline characteristicsSurgical resectionTerm survivorsCancer RegistryPoor prognosisSurgical interventionCancer CenterCancer mortalityDegree of differentiationCancer InstituteSurvival rateYounger ageLogistic regressionPatients
2014
Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT. Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: 918-925. PMID: 25585785, DOI: 10.1016/j.ijrobp.2014.06.066.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyCumulative incidence rateSingle-fraction groupUnresectable pancreatic adenocarcinomaBody radiation therapyPancreatic adenocarcinomaToxicity gradeSurvival rateLocal recurrenceIncidence rateRadiation therapySingle-fraction stereotactic body radiation therapyGastrointestinal toxicity gradeMajority of patientsGastrointestinal toxicityMedian survivalWorse survivalIndependent predictorsPancreatic cancerLocal controlPatientsAdenocarcinomaRecurrenceTherapyMonthsPostradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma
Shultz DB, Chan C, Shaffer JL, Kunz PL, Koong AC, Chang DT. Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Pancreas 2014, 43: 777-783. PMID: 24632549, DOI: 10.1097/mpa.0000000000000098.Peer-Reviewed Original ResearchConceptsPostoperative chemoradiotherapyPancreatic ductal adenocarcinomaDuctal adenocarcinomaNonmetastatic pancreatic ductal adenocarcinomaCA19-9 kineticsPretreatment CA19-9Carbohydrate antigen 19Definitive chemoradiotherapyRadiotherapy correlatesOverall survivalMultivariable analysisAntigen 19CA19-9Disease progressionPancreatic adenocarcinomaTreatment decisionsChemoradiotherapyPrognostic toolPatientsKinetics correlateAdenocarcinomaRT correlateFFPTTNProgression
2012
Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? Annals Of Surgical Oncology 2012, 20: 1631-1638. PMID: 23149854, DOI: 10.1245/s10434-012-2724-5.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overCaliforniaChemotherapy, AdjuvantFemaleGastrectomyHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm StagingProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesStomach NeoplasmsTreatment OutcomeYoung AdultConceptsAJCC/UICC staging systemUICC staging systemStaging systemStage IBLymph nodesGastric adenocarcinomaAJCC/UICC stageAJCC/UICC systemCurative-intent surgical resectionSeventh editionKaplan-Meier methodOverall survival probabilityStatewide Health PlanningCancer registry dataNew grouping systemAdjuvant chemotherapyAdjuvant radiotherapySurgical resectionMedian ageUICC stageAsian patientsDischarge abstractsMedian numberRegistry dataGastric cancerLong-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-Term Survivors of Gastric Cancer: A California Population-Based Study. Journal Of Clinical Oncology 2012, 30: 3507-3515. PMID: 22949151, DOI: 10.1200/jco.2011.35.8028.Peer-Reviewed Original ResearchConceptsDisease-specific survivalMedian disease-specific survivalGEJ cancerGastric cancerIntestinal histologyAsian/Pacific Islander raceNational Cancer Institute's SurveillanceCox proportional hazards modelEsophagus/cardiaCalifornia Cancer RegistryPacific Islander raceGastroesophageal junction adenocarcinomaKaplan-Meier curvesEnd Results ProgramCases of gastricSocioeconomic status quintileProportional hazards modelJunction adenocarcinomaPathologic characteristicsTerm survivorsCancer RegistryTumor characteristicsDiffuse histologyHispanic raceResults ProgramCapecitabine-Induced Chest Pain Relieved by Diltiazem
Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-Induced Chest Pain Relieved by Diltiazem. The American Journal Of Cardiology 2012, 110: 1623-1626. PMID: 22939579, DOI: 10.1016/j.amjcard.2012.07.026.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAntimetabolites, AntineoplasticAnus NeoplasmsCalcium Channel BlockersCapecitabineCarcinoma, Squamous CellChest PainColorectal NeoplasmsCoronary VasospasmDeoxycytidineDiltiazemElectrocardiographyFemaleFluorouracilFollow-Up StudiesHumansMaleMiddle AgedProdrugsSecondary PreventionTreatment OutcomeConceptsChest painAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarctionAnal squamous cell carcinomaSignificant coronary artery diseaseDiscontinuation of capecitabineElevation myocardial infarctionCoronary artery diseasePrimary colorectal adenocarcinomaSquamous cell carcinomaIschemia evaluationSecondary prophylaxisTroponin elevationArtery diseaseInitial presentationSustained reliefElectrocardiographic findingsCell carcinomaMyocardial infarctionColorectal adenocarcinomaPainPatientsChemotherapeutic agentsNovel management strategiesCapecitabinePancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Brooke Jeffrey R, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. Annals Of Surgical Oncology 2012, 19: 2295-2303. PMID: 22396008, DOI: 10.1245/s10434-012-2305-7.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenoma, Islet CellAdultAgedCalcinosisFemaleFollow-Up StudiesGastrinomaHumansInsulinomaLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingNeoplasms, Multiple PrimaryNeuroendocrine TumorsPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesStomach NeoplasmsTomography, X-Ray ComputedConceptsPancreatic neuroendocrine tumorsSynchronous liver metastasesLymph node metastasisLiver metastasesNode metastasisOverall survivalRadiographic calcificationsHigh-grade pancreatic neuroendocrine tumorsComputed tomography correlateIntermediate tumor gradeRegional lymph nodesPreoperative computed tomographyPresence of calcificationCurative intentFormal pancreatectomyMethodsFrom 1998Surgical resectionIndependent predictorsLymph nodesPrognostic significanceCalcified tumorClinicopathologic variablesNeuroendocrine tumorsPrimary tumorTumor gradeHER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population
Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population. Applied Immunohistochemistry & Molecular Morphology 2012, 20: 13-24. PMID: 21617522, PMCID: PMC6402787, DOI: 10.1097/pai.0b013e31821c821c.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBreast NeoplasmsEsophageal NeoplasmsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescenceIncidenceMaleMiddle AgedReceptor, ErbB-2Retrospective StudiesStomach NeoplasmsUnited StatesConceptsGastroesophageal junction cancerHER2-positive adenocarcinomaGastroesophageal junction carcinomaJunction cancerHER2 expressionHER2 statusClinical Oncology/CollegeHER2-positive gastricGastroesophageal junction adenocarcinomaGastric Cancer TrialIntestinal-type adenocarcinomaPrimary tumor siteMembranous staining patternHER2/CEP17 ratioPrimary gastric adenocarcinomaTissue microarray approachASCO/CAPHER2 gene amplificationHER2 protein expressionJunction adenocarcinomaDiffuse adenocarcinomaGastroesophageal junctionPatient survivalTherapeutic optionsIntestinal type
2011
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e595-e601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival RateConceptsIntensity-modulated radiotherapyLocal-regional control ratesPancreatic adenocarcinomaAdjuvant patientsDefinitive patientsControl rateSurvival rateGrade 3 late toxicityRecurrence-free survival ratesThree-dimensional conformal radiotherapyOverall survival rateProspective clinical trialsRecurrence-free survivalDurable disease controlPlanning target volumeGreater acute toxicityAcute toxicityLate toxicityOverall survivalSystemic therapyMedian agePancreatic cancerClinical trialsPrescription doseGrade 3Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer
Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC. Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: 181-188. PMID: 21549517, DOI: 10.1016/j.ijrobp.2010.05.006.Peer-Reviewed Original ResearchConceptsSingle-fraction stereotactic body radiotherapyAdvanced pancreatic cancerSequential gemcitabinePancreatic cancerGrade 3Local controlIntensity-modulated radiotherapy techniqueStereotactic body radiation therapyGreater nonhematologic toxicityLate grade 3Nonmetastatic pancreatic adenocarcinomaAcute grade 3Cycles of chemotherapyFraction Stereotactic Body Radiation TherapyExcellent local controlPhase II trialStereotactic body radiotherapyBody radiation therapyInternal target volumeInstitutional review boardNonhematologic toxicityAlive patientsII trialLocal progressionDuodenal perforation
2010
Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma
Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer 2010, 116: 5179-5187. PMID: 20665497, DOI: 10.1002/cncr.25481.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCarbonic Anhydrase IXCarbonic AnhydrasesCell HypoxiaCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleHumansImmunohistochemistryMaleMiddle AgedPancreatic NeoplasmsPoly(ADP-ribose) PolymerasesPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTetrahydrofolate DehydrogenaseTissue Array AnalysisConceptsProgression-free survivalOverall survivalPoly adenosine diphosphate-ribose polymerasePancreatic adenocarcinomaImproved OSImmunohistochemical expressionHypoxia markersImproved overall survivalCyclin-dependent kinase inhibitor 2AExpression of p16INK4aCarbonic anhydrase IXAdjuvant chemotherapyCurative resectionMedian survivalImproved survivalMargin statusClinical outcomesPrimary tumorPancreatic cancerUnivariate analysisSurgical specimensImmunohistochemical stainingTissue microarrayPositive stainingPatients
2004
Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus
Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy 2004, 60: 739-756. PMID: 15557950, DOI: 10.1016/s0016-5107(04)02167-4.Peer-Reviewed Original Research